Effects of the oral probiotic Familact on dyspnea management in COPD patients: A randomized controlled trial

IF 2.6 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart & Lung Pub Date : 2025-02-27 DOI:10.1016/j.hrtlng.2025.02.002

Mehdi Aghamohammadi , Samad Ghodrati , Nooshin Jalili , Roghayeh Jafari , Effat Rafiee , Koorosh Kamali , Mahsa Ghasemi , Javad Alizargar

{"title":"Effects of the oral probiotic Familact on dyspnea management in COPD patients: A randomized controlled trial","authors":"Mehdi Aghamohammadi , Samad Ghodrati , Nooshin Jalili , Roghayeh Jafari , Effat Rafiee , Koorosh Kamali , Mahsa Ghasemi , Javad Alizargar","doi":"10.1016/j.hrtlng.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests that oral probiotics may enhance the immune response in respiratory diseases, offering potential benefits in managing Chronic Obstructive Pulmonary Disease (COPD).</div></div><div><h3>Objectives</h3><div>This trial aims to evaluate whether the addition of the oral probiotic Familact to standard therapies significantly enhances dyspnea management in COPD patients compared to standard treatment alone.</div></div><div><h3>Methods</h3><div>In this single-blind randomized clinical trial 60 COPD patients randomly allocated into the control and intervention groups (<em>n</em> = 30). Over three months, the control group received standard treatment, while the intervention group received standard treatment plus oral Familact. Spirometry was conducted twice, and dyspnea was assessed four times using the Borg Scale Ratings (BORG) and Modified Medical Research Council Dyspnea Scale Scores in COPD patients (MMRC) scales and were evaluated using repeated measurement analysis.</div></div><div><h3>Results</h3><div>No significant change was observed in FEV1 post-intervention, but MMRC and BORG scores showed a statistically significant improvement in the intervention group compared to the control group (<em>P</em> < 0.01). Repeated measures tests based on estimated marginal means revealed significant MMRC differences within groups over time, with inter-group differences notable only between the first and second measurements. BORG showed significant within- and between-group differences at all time points, confirmed by post hoc tests.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that Familact, as an oral probiotic can significantly alleviate dyspnea in COPD patients, as reflected in notable improvements in BORG and MMRC scores. These findings underscore the potential of probiotics as an adjunctive therapy for COPD, particularly in improving patient-reported outcomes related to respiratory difficulty.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"71 ","pages":"Pages 63-68"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart & Lung","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147956325000299","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Emerging evidence suggests that oral probiotics may enhance the immune response in respiratory diseases, offering potential benefits in managing Chronic Obstructive Pulmonary Disease (COPD).

Objectives

This trial aims to evaluate whether the addition of the oral probiotic Familact to standard therapies significantly enhances dyspnea management in COPD patients compared to standard treatment alone.

Methods

In this single-blind randomized clinical trial 60 COPD patients randomly allocated into the control and intervention groups (n = 30). Over three months, the control group received standard treatment, while the intervention group received standard treatment plus oral Familact. Spirometry was conducted twice, and dyspnea was assessed four times using the Borg Scale Ratings (BORG) and Modified Medical Research Council Dyspnea Scale Scores in COPD patients (MMRC) scales and were evaluated using repeated measurement analysis.

Results

No significant change was observed in FEV1 post-intervention, but MMRC and BORG scores showed a statistically significant improvement in the intervention group compared to the control group (P < 0.01). Repeated measures tests based on estimated marginal means revealed significant MMRC differences within groups over time, with inter-group differences notable only between the first and second measurements. BORG showed significant within- and between-group differences at all time points, confirmed by post hoc tests.

Conclusion

This study demonstrates that Familact, as an oral probiotic can significantly alleviate dyspnea in COPD patients, as reflected in notable improvements in BORG and MMRC scores. These findings underscore the potential of probiotics as an adjunctive therapy for COPD, particularly in improving patient-reported outcomes related to respiratory difficulty.

查看原文本刊更多论文

口服益生菌Familact对COPD患者呼吸困难管理的影响：一项随机对照试验

背景：越来越多的证据表明，口服益生菌可能增强呼吸系统疾病的免疫反应，对慢性阻塞性肺疾病（COPD）的治疗有潜在的益处。目的：本试验旨在评估与单独标准治疗相比，在标准治疗中加入口服益生菌Familact是否能显著增强COPD患者的呼吸困难管理。方法将60例慢性阻塞性肺病患者随机分为对照组和干预组（n = 30）。3个月以上，对照组给予标准治疗，干预组给予标准治疗加口服Familact。使用Borg量表评分（Borg）和改良医学研究委员会COPD患者呼吸困难量表评分（MMRC）进行2次肺活量测定，4次呼吸困难评估，并使用重复测量分析进行评估。结果干预后FEV1无明显变化，但干预组MMRC和BORG评分较对照组有显著改善(P <；0.01)。基于估计边际均值的重复测量测试显示，随着时间的推移，组内MMRC存在显著差异，组间差异仅在第一次和第二次测量之间显著。事后测试证实，BORG在所有时间点均显示出显著的组内和组间差异。结论本研究表明，Familact作为一种口服益生菌可以显著缓解COPD患者的呼吸困难，这体现在BORG和MMRC评分的显著改善上。这些发现强调了益生菌作为COPD辅助治疗的潜力，特别是在改善患者报告的与呼吸困难相关的结果方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart & Lung 医学-呼吸系统

CiteScore

4.60

自引率

3.60%

发文量

184

审稿时长

35 days

期刊介绍： Heart & Lung: The Journal of Cardiopulmonary and Acute Care, the official publication of The American Association of Heart Failure Nurses, presents original, peer-reviewed articles on techniques, advances, investigations, and observations related to the care of patients with acute and critical illness and patients with chronic cardiac or pulmonary disorders. The Journal''s acute care articles focus on the care of hospitalized patients, including those in the critical and acute care settings. Because most patients who are hospitalized in acute and critical care settings have chronic conditions, we are also interested in the chronically critically ill, the care of patients with chronic cardiopulmonary disorders, their rehabilitation, and disease prevention. The Journal''s heart failure articles focus on all aspects of the care of patients with this condition. Manuscripts that are relevant to populations across the human lifespan are welcome.